FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308293485> ?p ?o ?g. }

• W4308293485 endingPage "47" @default.
• W4308293485 startingPage "35" @default.
• W4308293485 abstract "Premenopausal women with idiopathic osteoporosis (PreMenIOP) have marked deficits in skeletal microstructure. We have reported that sequential treatment with teriparatide and denosumab improves central skeletal bone mineral density (BMD) by dual-energy X-ray absorptiometry and central QCT in PreMenIOP. We conducted preplanned analyses of high-resolution peripheral quantitative computed tomography (HR-pQCT) scans from teriparatide and denosumab extension studies to measure effects on volumetric BMD (vBMD), microarchitecture, and estimated strength at the distal radius and tibia. Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study. HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months. After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months. Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab. Changes after sequential teriparatide and denosumab were secondary outcomes. After teriparatide, significant improvements were seen in tibial trabecular number (3.3%, p = 0.01), cortical area and thickness (both 2.7%, p < 0.001), and radial trabecular microarchitecture (number: 6.8%, thickness: 2.2%, separation: -5.1%, all p < 0.02). Despite increases in cortical porosity and decreases in cortical density, whole-bone stiffness and failure load increased at both sites. After denosumab, increases in total (3.5%, p < 0.001 and 3.3%, p = 0.02) and cortical vBMD (1.7% and 3.2%; both p < 0.01), and failure load (1.1% and 3.6%; both p < 0.05) were seen at tibia and radius, respectively. Trabecular density (3.5%, p < 0.001) and number (2.4%, p = 0.03) increased at the tibia, while thickness (3.0%, p = 0.02) increased at the radius. After 48 months of sequential treatment, significant increases in total vBMD (tibia: p < 0.001; radius: p = 0.01), trabecular microstructure (p < 0.05), cortical thickness (tibia: p < 0.001; radius: p = 0.02), and whole bone strength (p < 0.02) were seen at both sites. Significant increases in total vBMD and bone strength parameters after sequential treatment with teriparatide followed by denosumab support the use of this regimen in PreMenIOP. © 2022 American Society for Bone and Mineral Research (ASBMR)." @default.
• W4308293485 created "2022-11-10" @default.
• W4308293485 creator A5016488392 @default.
• W4308293485 creator A5039735451 @default.
• W4308293485 creator A5042971986 @default.
• W4308293485 creator A5048333253 @default.
• W4308293485 creator A5052478195 @default.
• W4308293485 creator A5068373098 @default.
• W4308293485 creator A5069333159 @default.
• W4308293485 creator A5075125176 @default.
• W4308293485 creator A5076365121 @default.
• W4308293485 creator A5085439926 @default.
• W4308293485 creator A5090827674 @default.
• W4308293485 date "2022-11-24" @default.
• W4308293485 modified "2023-10-16" @default.
• W4308293485 title "Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by <scp>HR‐pQCT</scp>" @default.
• W4308293485 cites W1500340499 @default.
• W4308293485 cites W1702563725 @default.
• W4308293485 cites W1965154023 @default.
• W4308293485 cites W1966877738 @default.
• W4308293485 cites W1967727095 @default.
• W4308293485 cites W1972192940 @default.
• W4308293485 cites W1975033453 @default.
• W4308293485 cites W1976387068 @default.
• W4308293485 cites W1976854024 @default.
• W4308293485 cites W1979462438 @default.
• W4308293485 cites W1993457878 @default.
• W4308293485 cites W1993548621 @default.
• W4308293485 cites W1997367893 @default.
• W4308293485 cites W1999889262 @default.
• W4308293485 cites W2009222457 @default.
• W4308293485 cites W2014973716 @default.
• W4308293485 cites W2015247179 @default.
• W4308293485 cites W2028065902 @default.
• W4308293485 cites W2028762482 @default.
• W4308293485 cites W2030294284 @default.
• W4308293485 cites W2032283776 @default.
• W4308293485 cites W2051147526 @default.
• W4308293485 cites W2070459338 @default.
• W4308293485 cites W2072027816 @default.
• W4308293485 cites W2073721888 @default.
• W4308293485 cites W2081070012 @default.
• W4308293485 cites W2090408873 @default.
• W4308293485 cites W2104307326 @default.
• W4308293485 cites W2105510043 @default.
• W4308293485 cites W2112779928 @default.
• W4308293485 cites W2113523811 @default.
• W4308293485 cites W2115028313 @default.
• W4308293485 cites W2117268256 @default.
• W4308293485 cites W2117917672 @default.
• W4308293485 cites W2125521874 @default.
• W4308293485 cites W2128569032 @default.
• W4308293485 cites W2148508563 @default.
• W4308293485 cites W2160005424 @default.
• W4308293485 cites W2170373155 @default.
• W4308293485 cites W2295122297 @default.
• W4308293485 cites W2347192667 @default.
• W4308293485 cites W2793857860 @default.
• W4308293485 cites W2908475062 @default.
• W4308293485 cites W2978676553 @default.
• W4308293485 cites W3048703611 @default.
• W4308293485 cites W3082325025 @default.
• W4308293485 cites W3127036224 @default.
• W4308293485 cites W3185774732 @default.
• W4308293485 cites W3216944744 @default.
• W4308293485 cites W4223584970 @default.
• W4308293485 cites W4223932572 @default.
• W4308293485 doi "https://doi.org/10.1002/jbmr.4739" @default.
• W4308293485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36335582" @default.
• W4308293485 hasPublicationYear "2022" @default.
• W4308293485 type Work @default.
• W4308293485 citedByCount "3" @default.
• W4308293485 countsByYear W43082934852023 @default.
• W4308293485 crossrefType "journal-article" @default.
• W4308293485 hasAuthorship W4308293485A5016488392 @default.
• W4308293485 hasAuthorship W4308293485A5039735451 @default.
• W4308293485 hasAuthorship W4308293485A5042971986 @default.
• W4308293485 hasAuthorship W4308293485A5048333253 @default.
• W4308293485 hasAuthorship W4308293485A5052478195 @default.
• W4308293485 hasAuthorship W4308293485A5068373098 @default.
• W4308293485 hasAuthorship W4308293485A5069333159 @default.
• W4308293485 hasAuthorship W4308293485A5075125176 @default.
• W4308293485 hasAuthorship W4308293485A5076365121 @default.
• W4308293485 hasAuthorship W4308293485A5085439926 @default.
• W4308293485 hasAuthorship W4308293485A5090827674 @default.
• W4308293485 hasConcept C126322002 @default.
• W4308293485 hasConcept C126894567 @default.
• W4308293485 hasConcept C134018914 @default.
• W4308293485 hasConcept C2776286101 @default.
• W4308293485 hasConcept C2776541429 @default.
• W4308293485 hasConcept C2776886416 @default.
• W4308293485 hasConcept C2777308945 @default.
• W4308293485 hasConcept C2777425516 @default.
• W4308293485 hasConcept C2779329777 @default.
• W4308293485 hasConcept C71924100 @default.
• W4308293485 hasConceptScore W4308293485C126322002 @default.
• W4308293485 hasConceptScore W4308293485C126894567 @default.
• W4308293485 hasConceptScore W4308293485C134018914 @default.

• next